Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Centessa Pharmaceuticals PLC ADR

Healthcare US CNTA

39.835USD
-0.065(0.16%)

Last update at 2026-06-03T20:00:00Z

Day Range

39.7839.92
LowHigh

52 Week Range

10.9540.26
LowHigh

Fundamentals

  • Previous Close 39.90
  • Market Cap6110.70M
  • Volume809188
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-207.37101M
  • Revenue TTM15.00M
  • Revenue Per Share TTM0.11
  • Gross Profit TTM 15.00M
  • Diluted EPS TTM-1.46

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -195.71300M -232.91300M -176.14100M -216.95400M -380.95700M
Minority interest - - - - -
Net income -197.53200M -235.75700M -151.08500M -216.20700M -381.07100M
Selling general administrative 50.47M 50.81M 53.73M 55.20M 42.89M
Selling and marketing expenses - - 0.60M - -
Gross profit 15.00M -0.94240M 6.85M - -
Reconciled depreciation 0.92M 0.94M 0.60M 0.13M -
Ebit - -222.82300M -166.23500M -212.26300M -379.78500M
Ebitda -207.69200M -221.88100M -165.42500M -207.94100M -379.75100M
Depreciation and amortization - 0.94M 0.81M 4.32M 0.03M
Non operating income net other - - - - -
Operating income -207.69200M -201.05500M -171.28300M -212.26300M -379.78500M
Other operating expenses 222.69M 201.06M 178.14M 210.28M 138.55M
Interest expense 11.46M 10.09M 9.91M 7.03M 1.17M
Tax provision 1.82M 2.84M -26.86400M -0.74700M -
Interest income 20.53M 14.02M 10.48M - -
Net interest income 9.07M 3.93M -1.95700M -7.03300M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.82M 2.84M -25.05600M -0.74700M 0.11M
Total revenue 15.00M 0.00000M 6.85M 0.00000M -
Total operating expenses 222.69M 201.06M 178.14M 210.28M 138.55M
Cost of revenue - 0.94M 0.81M - -
Total other income expense net 11.98M -31.85800M -4.85800M -4.69100M -1.17200M
Discontinued operations - - - - -
Net income from continuing ops -197.53200M -235.75700M -157.42100M -216.20700M -
Net income applicable to common shares - - - -216.20700M -381.07100M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 687.50M 576.80M 362.97M 444.31M 629.63M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 73.30M 8.94M 19.39M 3.27M 0.99M
Total liab 160.63M 175.25M 126.72M 108.14M 138.08M
Total stockholder equity 526.86M 401.55M 236.24M 336.17M 491.55M
Deferred long term liab - - - - -
Other current liab 35.35M 50.02M 27.57M 24.50M 16.57M
Common stock 0.41M 0.36M 0.27M 0.27M 0.25M
Capital stock 0.41M 0.36M 0.27M 0.27M 0.25M
Retained earnings -1186.23400M -988.70200M -752.94500M -601.86000M -385.65300M
Other liab - - - - 37.74M
Good will - - - - -
Other assets - - - 5.39M 0.70M
Cash 61.30M 383.22M 128.03M 393.64M 595.08M
Cash and equivalents - - - - -
Total current liabilities 42.94M 58.00M 39.38M 38.34M 24.64M
Current deferred revenue - - - - -
Net debt -53.72600M -265.99500M -43.44200M -323.84400M -519.38200M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total 7.57M 117.23M 84.59M 69.80M 75.70M
Other stockholder equity 1709.98M 1385.67M 987.42M 939.26M 876.27M
Property plant equipment - - - 1.17M 0.16M
Total current assets 367.88M 536.41M 315.09M 393.64M 595.08M
Long term investments 282.55M 0.00000M - - -
Net tangible assets - - - 336.17M 491.55M
Short term investments 233.28M 98.96M 128.52M - -
Net receivables - 45.30M 39.15M 26.72M 16.81M
Long term debt 110.09M 108.94M 75.70M 69.80M 75.70M
Inventory - - 0.00000M -29.99400M -17.80700M
Accounts payable 7.58M 7.14M 11.81M 13.84M 8.06M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.71M 4.21M 1.49M -1.49700M 0.69M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.44M 2.05M 2.55M 49.49M 34.39M
Deferred long term asset charges - - - - -
Non current assets total 319.62M 40.39M 47.88M 50.66M 34.55M
Capital lease obligations 8.29M 8.29M 8.89M - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -418.16000M 31.27M -109.17500M -0.93100M -
Change to liabilities - - - 6.35M 3.80M
Total cashflows from investing activities -418.53100M 31.27M -127.00400M -0.93100M 63.26M
Net borrowings 0.00000M -0.76200M 0.00000M - 73.65M
Total cash from financing activities 291.53M 364.75M 21.12M 0.46M 660.15M
Change to operating activities - - - -9.18200M -9.82600M
Net income -197.53200M -235.75700M -151.08500M -216.20700M -381.07100M
Change in cash -321.26800M 255.19M -265.61400M -201.43800M 590.12M
Begin period cash flow 383.22M 128.03M 393.64M 595.08M 4.97M
End period cash flow 61.95M 383.22M 128.03M 393.64M 595.08M
Total cash from operating activities -193.81700M -142.05500M -160.34200M -200.54600M -135.10900M
Issuance of capital stock 275.36M 359.61M 14.56M 0.00000M -
Depreciation 0.92M 0.94M 0.81M 0.13M 0.03M
Other cashflows from investing activities - 171.83M - 0.21M 0.21M
Dividends paid - - - - -
Change to inventory - - -0.00000M - -
Change to account receivables 2.91M -6.60100M -12.13887M - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 291.53M 5.91M 0.31M 0.46M 660.15M
Change to netincome - - - 18.36M 251.74M
Capital expenditures 0.37M 0.03M 0.17M 1.14M 0.19M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -51.23600M 22.10M -18.85800M -2.83100M 231.08M
Stock based compensation 30.96M 33.55M 29.39M 24.96M 14.85M
Other non cash items 20.56M 34.46M 6.03M -3.74700M 231.08M
Free cash flow -194.18800M -142.08900M -160.51100M -201.68300M -135.29500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CNTA
Centessa Pharmaceuticals PLC ADR		 -0.065 0.16% 39.84 - - 407.38 11.60 395.63 1.12
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Centessa Pharmaceuticals PLC ADR

1 Ashley Road, Altrincham, United Kingdom, WA14 2DT

Key Executives

Name Title Year Born
Dr. Saurabh Saha M.D., Ph.D. CEO & Director 1977
Dr. Gregory M. Weinhoff M.B.A., M.D., MBA Principal Accounting Officer & CFO 1971
Dr. Antoine Yver M.D., M.Sc., MSc Exec. VP & Chairman of Devel. 1958
Dr. Thomas S. Templeman Ph.D. Chief Technology Officer 1960
Dr. David M. Chao Ph.D. Chief Admin. Officer 1968
Ms. Kristen K. Sheppard Esq., J.D. Sr. VP of Investor Relations & Corp. Communications NA
Mr. Iqbal J. Hussain L.L.B. Gen. Counsel, Chief Compliance Officer & Corp. Sec. 1981
Ms. Karen M. Anderson Chief People Officer 1967
Ms. Tia L. Bush Chief Quality Officer 1971
Dr. David John Grainger Ph.D. Chief Innovation Officer 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions